Tania Jain
About
Tania Jain is a scholar working on Hematology, Oncology and Genetics.
According to data from OpenAlex, Tania Jain has authored 96 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Hematology, 46 papers in Oncology and 30 papers in Genetics. Recurrent topics in Tania Jain's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (26 papers), CAR-T cell therapy research (25 papers) and Acute Myeloid Leukemia Research (22 papers). Tania Jain is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (26 papers), CAR-T cell therapy research (25 papers) and Acute Myeloid Leukemia Research (22 papers). Tania Jain collaborates with scholars based in United States, United Kingdom and Spain. Tania Jain's co-authors include Mark R. Litzow, Frederick L. Locke, Timothy S. Olson, Bipin N. Savani, Jeanne Palmer, Khaled Sanber, Ruben A. Mesa, Miguel‐Angel Perales, Richard J. Jones and Belal Firwana and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Tania Jain
91 papers receiving 1.2k citations
Peers
Tania Jain
Basem M. William United States
Henrique Bittencourt Canada
Ignacio Lorenzo Spain
Felix Keil Austria
Matthew D. Seftel Canada
Betty K. Hamilton United States
Ivetta Danylesko Israel
Abraham S. Kanate United States
Byung Soo Kim South Korea
M. J. Barnett Canada
Citations per year, relative to Tania Jain Tania Jain (= 1×)
peers
Basem M. William
Countries citing papers authored by Tania Jain
Since
Specialization
Citations
This map shows the geographic impact of Tania Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tania Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tania Jain more than expected).
Fields of papers citing papers by Tania Jain
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tania Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tania Jain. The network helps show where Tania Jain may publish in the future.
Co-authorship network of co-authors of Tania Jain
This figure shows the co-authorship network connecting the top 25 collaborators of Tania Jain. A scholar is included among the top collaborators of Tania Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tania Jain. Tania Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mo, Shirley, Alexander J. Ambinder, Amy E. DeZern, et al.. (2025). DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors. Blood. 146(Supplement 1). 1710–1710.
2.
Malki, Monzr M. Al, Alla Keyzner, Yibin Chen, et al.. (2025). TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation and Cellular Therapy. 31(2). S59–S60.
3.
Dioverti, M. Veronica, et al.. (2024). Mitigating and managing infection risk in adults treated with CAR T-cell therapy. Hematology. 2024(1). 116–125.
4.
Vachhani, Pankit, Raajit K. Rampal, Terrence Bradley, et al.. (2024). POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib. Blood. 144(Supplement 1). 1808.2–1808.2.
5.
Shahid, Zainab, Tania Jain, M. Veronica Dioverti, et al.. (2024). Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies. Transplantation and Cellular Therapy. 30(10). 955–969.
6.
DeZern, Amy E., Marianna Zahurak, Heather J. Symons, et al.. (2023). Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 141(25). 3031–3038.
7.
Karantanos, Theodoros, Donna M. Williams, Shruti Chaturvedi, et al.. (2023). Characterization of myeloproliferative neoplasms in the paediatric and young adult population. British Journal of Haematology. 201(3). 449–458.
8.
Kanate, Abraham S., Navneet S. Majhail, Zachariah DeFilipp, et al.. (2023). Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 29(10). 594–597.
9.
Tsai, Hua‐Ling, Ephraim J. Fuchs, Lode J. Swinnen, et al.. (2022). Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source. Transplantation and Cellular Therapy. 29(4). 267.e1–267.e5.
10.
Fuchs, Ephraim J., Leo Luznik, Javier Bolaños‐Meade, et al.. (2022). Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. British Journal of Haematology. 199(5). 720–727.
11.
Jain, Tania, Tristan Knight, Laurie Davis, et al.. (2022). American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy. Transplantation and Cellular Therapy. 28(3). 125–133.
12.
Ambinder, Alexander J., Tania Jain, Hua‐Ling Tsai, et al.. (2022). HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Advances. 6(14). 4335–4346.
13.
Perales, Miguel‐Angel, Larry D. Anderson, Tania Jain, et al.. (2022). Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 28(9). 546–559.
14.
Zahurak, Marianna, Maria Bettinotti, Syed Abbas Ali, et al.. (2021). Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 27(11). 909.e1–909.e6.
15.
Karantanos, Theodoros, Lukasz P. Gondek, Ravi Varadhan, et al.. (2021). Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. British Journal of Haematology. 193(6). 1142–1150.
16.
Karantanos, Theodoros, Hua‐Ling Tsai, Lukasz P. Gondek, et al.. (2020). Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN). Blood. 136(Supplement 1). 40–40.
17.
Mughal, Tariq I., Naveen Pemmaraju, Bethan Psaila, et al.. (2020). Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematological Oncology. 38(5). 654–664.
18.
Sonbol, Mohamad Bassam, Tania Jain, Belal Firwana, et al.. (2019). Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. BMJ Supportive & Palliative Care. 9(4). 425–433.
19.
Jain, Tania, Mohamad Bassam Sonbol, Belal Firwana, et al.. (2018). High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation. 25(2). 239–247.
20.
Hilal, Talal, Zhen Wang, Diana Almader‐Douglas, et al.. (2018). Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta‐analysis. American Journal of Hematology. 93(10). 1220–1226.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Basem M. William Breakdown of academic impact, for papers by Henrique Bittencourt Breakdown of academic impact, for papers by Ignacio Lorenzo Breakdown of academic impact, for papers by Felix Keil Breakdown of academic impact, for papers by Matthew D. Seftel Breakdown of academic impact, for papers by Betty K. Hamilton Breakdown of academic impact, for papers by Ivetta Danylesko Breakdown of academic impact, for papers by Abraham S. Kanate Breakdown of academic impact, for papers by Byung Soo Kim Breakdown of academic impact, for papers by M. J. Barnett